Human papillomavirus (HPV) tests are less likely to miss cases of precancerous cervical changes, yet they lead to more unnecessary referrals, according to a Cochrane review of 40 studies involving more than 140,000 women. Among the findings:
- For every 1,000 women screened, around 20 will have precancerous changes.
- The HPV test will correctly identify 16 and miss 4 of these women.
- The Pap test will identify 12 and miss 8 women.
- For every 1,000 women screened, 980 will not have precancerous changes.
- The HPV test will correctly identify 879 women, but 101 will be incorrectly told that they have a lesion.
- The Pap test will correctly identify 951 women, but 29 will be incorrectly told that they have a lesion.
Koliopoulos G, Nyaga V, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database of Systematic Reviews. 2017, Issue 8. Art. No.: CD008587. doi:10.1002/14651858.CD008587.pub2.
This Week's Must Reads
Oncologists raise access concerns about new mobile technology, Article based on interviews.
Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018
Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142
Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits
The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32
Must Reads in Gynecologic Cancer
CD8+ Tumor-Infiltrating Lymphocytes and Ovarian Ca, JAMA Oncol; ePub 2017 Oct 12; OTTA Consortium
Lymph Node Removal During Endometrial Ca Surgery, Cochrane; 2017 Oct 2; Frost, Webster, et al
Cochrane on Reducing Neoplasia in Molar Pregnancy, Cochrane; 2017 Sep 11; Wang, Fu, Hu, et al
FDA Approves First Biosimilar to Treat Cancer, FDA news release; 2017 Sep 14
HPV vs Pap Test for Cervical Cancer Screening, Cochrane; 2017 Aug 10; Koliopoulos, Nyaga, et al